Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA requested public comment on how to measure and evaluate the real-world performance of AI-enabled medical devices.
The request focused on practical ways to detect, assess and mitigate performance changes over time so AI-enabled devices remain safe and effective across their life cycle.
The issue is central to clinical AI. Model performance can shift when patient populations, workflows, sensors or clinical practice change after deployment.
Why It Matters
AI medical devices require lifecycle oversight, not just one-time premarket evaluation.
What to Watch
Watch postmarket monitoring standards, drift-detection expectations and how device makers document real-world performance.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAAI Medical DevicesDigital HealthPostmarket Monitoring